Henagliflozin

Cat. No.:	HY-123011
CAS No.:	1623804-44-3
Molecular Formula:	$C_{22}H_{24}ClFO_7$
Molecular Weight:	454.87
Target:	SGLT
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC_{50} values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research[1].
In Vivo	Henagliflozin (SHR3824) (p.o., 0.1-3.0 mg/kg, once) improves glucose tolerance in a dose-dependent manner in normal mice after exposure to glucose challenge[1]. Henagliflozin (SHR3824) (p.o., 0.3-3.0 mg/kg, once daily, 41 days) increases urinary glucose excretion in a dose-dependent manner and significantly reduces blood glucose levels in GK rats, with no effect on body weight or food intake. The HbA1c values of GK rats treated with 0.3, 1.0 or 3.0 mg/kg are 5.47%, 5.19% and 5.04%, respectively[1]. Henagliflozin (SHR3824) (p.o., 0.3-3.0 mg/kg, once daily, 43 days) causes a dose-dependent increase in urinary output and urinary glucose excretion in db/db mice, with a concomitant decrease in plasma glucose levels and no effect on body weight or food intake. The doses of 0.3, 1.0 or 3.0 mg/kg results in significant reductions in non-fasting and fasting glucose levels of 24.7%, 28.2% or 35.1% and 49.5%, 57.8% or 62.9%, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pang-ke Yan, et al. SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models. Acta Pharmacol Sin. 2014 May;35(5):613-24.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA